Today: Spark Therapeutics Inc. (ONCE) Given Consensus Rating of “Hold” by Analysts

Today: Spark Therapeutics Inc. (ONCE) Given Consensus Rating of “Hold” by Analysts

Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) have received an average rating of “Hold” from the fourteen ratings firms that are covering the firm. Three analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $60.17.

ONCE has been the subject of several research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $94.00 price objective on shares of Spark Therapeutics in a research report on Friday, November 4th. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a research report on Friday, August 5th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Spark Therapeutics in a research report on Monday, November 7th. Zacks Investment Research cut shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Finally, Wedbush reissued an “underperform” rating and issued a $29.00 price objective (up from $28.00) on shares of Spark Therapeutics in a research report on Wednesday, August 10th.

In related news, insider Barge Joseph La sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $60.14, for a total transaction of $180,420.00. Following the completion of the transaction, the insider now owns 8,325 shares in the company, valued at approximately $500,665.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Katherine A. High sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $60.37, for a total transaction of $603,700.00. Following the transaction, the insider now owns 220,500 shares in the company, valued at approximately $13,311,585. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Emerald Acquisition Ltd. bought a new position in shares of Spark Therapeutics during the second quarter worth about $633,000. AMG National Trust Bank bought a new position in shares of Spark Therapeutics during the second quarter worth about $256,000. Swiss National Bank raised its position in shares of Spark Therapeutics by 23.2% in the second quarter. Swiss National Bank now owns 36,600 shares of the company’s stock worth $1,871,000 after buying an additional 6,900 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Spark Therapeutics during the second quarter worth about $124,000. Finally, California State Teachers Retirement System raised its position in shares of Spark Therapeutics by 91.2% in the second quarter. California State Teachers Retirement System now owns 35,988 shares of the company’s stock worth $1,840,000 after buying an additional 17,165 shares during the last quarter. Institutional investors and hedge funds own 84.40% of the company’s stock.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 1.89% during midday trading on Monday, hitting $55.47. 183,774 shares of the company traded hands. Spark Therapeutics has a 52 week low of $21.20 and a 52 week high of $65.99. The company has a 50-day moving average price of $53.56 and a 200-day moving average price of $54.23. The stock’s market capitalization is $1.71 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by $0.06. The company earned $1.30 million during the quarter, compared to analysts’ expectations of $1.26 million. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. Spark Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the firm earned ($0.70) earnings per share. Analysts anticipate that Spark Therapeutics will post ($4.17) earnings per share for the current fiscal year.

Related posts

Leave a Comment